Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTAFR | P25105 | 18/20 | 0.69 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Israpafant SCHEMBL8792967 | 1.00 | PTAFR (0.69) | PTAFROPRK1PDE4DCYP3A4ALOX15 | |
| Israpafant SCHEMBL121587 | 1.00 | PTAFR (0.69) | PTAFROPRK1PDE4DCYP3A4ALOX15 | |
| Israpafant SCHEMBL121588 | 1.00 | PTAFR (0.69) | PTAFROPRK1PDE4DCYP3A4ALOX15 | |
| Israpafant SCHEMBL8794591 | 0.99 | PTAFR (0.68) | PTAFROPRK1PDE4DCYP3A4ALOX15 | |
| SCHEMBL9374585 | 0.92 | PTAFR (0.58) | PTAFROPRK1PDE4DCYP3A4ALOX15 | |
| Israpafant SCHEMBL8792589 | 0.90 | PTAFR (0.57) | PTAFROPRK1PDE4DCYP3A4ALOX15 | |
| SCHEMBL8878479 | 0.90 | PTAFR (0.67) | PTAFROPRK1PDE4DCYP3A4ALOX15 | |
| SCHEMBL9374425 | 0.89 | PTAFR (0.64) | PTAFROPRK1PDE4DCYP3A4ALOX15 | |
| SCHEMBL8877687 | 0.89 | PTAFR (0.57) | PTAFROPRK1PDE4DCYP3A4ALOX15 | |
| SCHEMBL8126816 | 0.89 | PTAFR (0.66) | PTAFROPRK1PDE4DCYP3A4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250283048-A1 | PLATELET-ACTIVATING FACTOR BLOCKADE INHIBITS TUMOR GROWTH | THE JOHNS HOPKINS UNIVERSITY | 2025-09-11 | — | — | US | disclosed |
| WO-2023215785-A1 | PLATELET-ACTIVATING FACTOR BLOCKADE INHIBITS TUMOR GROWTH | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250283048-A1 | PLATELET-ACTIVATING FACTOR BLOCKADE INHIBITS TUMOR GROWTH | PTAFR, PTGFR, PTGIR | PTAFR 1/4885OPRK1 2309/4885PDE4D 1610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.